Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Nanoform, Audiocast with teleconference, Q2'24

By Inderes8/29/2024, 12:00 PM
Nanoform Finland

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Henry von Hartmann
00:02 - 00:55

Good afternoon all, and a warm welcome to Nanoform's second quarter 2024 report presentation. My name is Henry von Hartmann, and I'm your Director of Investor Relations. Today, our CEO Edward Hæggström, CFO Albert Hæggström, and Chief Commercial Officer Christian Jones will present to you. This presentation is being webcast through Financial Hearings. Additionally, there is the possibility to call in analysts by phone. The presentation slides are shown throughout the webcast, and they can also be found on our web page in the investor section. After the presentation, we will hold a Q&A session, and it will be possible to ask questions by calling in. We will start today with an introduction to Nanoform, followed by the financials. And then we conclude with commercial. With these words, our CEO and founder, Professor Edward Hæggström. Welcome everyone to our Q2 2024 interim report presentation.

Edward Hæggström
00:55 - 05:54

Thank you, Henry. And welcome also on my behalf. Next slide, please. So, we work in the pharma industry, which faces an issue with too few medicines being developed each year despite significant R&D investment. Next, please. The reason for this is something called poor bioavailability, which means that an otherwise potent drug is not taken up by the body where it can do some good. This problem is large and it's growing. And this is the problem that we address. Next, please. We address it by making coarse powder into fine powder. As you can see here, you need to go deep into the nanometer range in order to achieve the desired effect. That is what we can do. Next, Nanoform has four platform technologies: one for small molecules, one for large molecules, one for nanoformulation, and one for AI. On the small molecule side, we improve bioavailability. As outlined before, the large molecule size is significant. The strongest driver is that we can improve the drug load. We can make it higher. This means that we can either have smaller infusions or we can have smaller pills. For instance, the nano formulation part is really aimed at optimizing the size to work effectively. There is a size effect that modulates the way the drug interacts with the body. On the AI side, it's possible to use in silico approaches to select winners and adjust the settings correctly early on. Next slide, please. A cascade of benefits follows, allowing new drugs to come to market, reducing dosages, and decreasing side effects. We can achieve patent expansions and prolongations for our customers. We can reduce production costs and CapEx requirements by building smaller factories. Additionally, we can increase environmental sustainability. Next, please. We can enable new drugs and improve existing ones. We can also give unsuccessful drug candidates a second chance. There are many candidates that can be improved. If we take a look at this slide, we can see that we have already accomplished a lot in 2024. The first bullet point discusses preparing to market medicines. We do this by creating what we call product kernels. It's important to remember that Nanoform works with new drugs, existing molecules, and those that have not yet been marketed. We collaborate with commercialization partners and development partners. The first contracts are expected to be signed in 2024. We have also seen increased biologics traction following the Takeda presentation earlier in May. We have signed several new customer projects, and we have seen interest in multi-API projects where multiple APIs are tested simultaneously. API stands for Active Pharmaceutical Ingredient, which is the component in the medication that provides therapeutic effects. We were awarded the GMP Quality Control Lab certificate. This certification allows us to provide faster analyses And offer a lower cost position to our customers. We have been conducting GMP manufacturing in a two-shift pattern, producing for the registration batches of the program. This year, we are ten times faster than last year. We are on track for the 2024 business targets, and much of our work is now focused on making nanoenzalutamide the first nanomedicine to reach the market. This is expected to happen by 2027 in the EU and by 2028 in the USA over the next five years. We are preparing to launch Nanoform products in collaboration with our partners. First, we work with development partners and then with commercialization partners. Next slide, please. This is where I hand over to Albert.

Albert Hæggström
05:55 - 16:41

Thank you, Edward. Let's first review some financial numbers and then examine the product kernels here on the left-hand side; you can see that we have added a few percent to our staff. These additions are mainly within the formulation and biologics units. However, you can also see that the growth rate in personnel has decreased because we believe we now have the critical mass. We currently have 170 employees. With that, we are capable of accomplishing many tasks on the right-hand side. There are some lines, both on the GAAP and non-GAAP side, that we have not yet commissioned. And so, the number will still go up without increased investments. Here, we feel we have a strong fleet of nanoforming lines where we can conduct numerous projects annually. If we move to proposals sent and projects signed, you can see that the fluctuation between the quarters is quite high, if you look at the right-hand side. You have some quarters where we only signed one or two, and then we have some quarters where we can sign ten. During this year, it's clear that the third quarter will be a very good quarter. And potentially, we will have a clear new record in a quarter. But when it comes to the number of signings, you can also see that we have reached a level where we send some 70 new proposals per year. This is mainly on the small molecule side. But now, as I've said, we are seeing more and more traction on the biologics side and that should help that number go up. Then, concerning signings, we also know that we have reached a level of about 20 on an annual basis, and we have every year an increased number. We also believe that this year we will have a higher number than last year when it comes to signings during the year. Regarding the revenue per quarter or revenue rolling 12 months, there have not been significant changes during the last quarter. If we then go to revenue, we observed a small sequential increase in the second quarter. While the 12-month rolling still was down slightly. Now, with the comps getting easier in the second half, And we also see more traction when it comes to signings. And, of course, when we sign deals around nanoenzalutamide, that will have an impact later on in the year. So, we expect the numbers to start to go up during the second half of the year. When it comes to the cost of goods and the gross margin, We obtained the license from FIMEA. And that means that we don't have to spend money on the GMP, QC with outside partners; we can now start to enforce it. And that means that already in the fourth quarter, we will see whether we can return to the levels we saw before we started the non-oil campaign. But we feel positive about this; in the coming months, we will be able to enforce the GMP, QC, and therefore the gross margin should return to the good level we have seen previously. This is very beneficial for us; it saves money and time and gives us more control over the process when it comes to GMP manufacturing and quality control within it. On the operating free cash flow, we observed a small improvement again. You can see that every quarter, we have improved. You can also see on the right-hand side that the rolling 12 months have improved. Of course, this is despite the fact that we have created many kernels. We have done a lot of work and have not yet seen the top-line impact. So when the top-line income impact comes from signing deals and getting more GMP projects, then the improvement will be faster. We have a strong balance sheet with more than €50 million in cash and short-term government bonds, and we have no debt. Here are the short-term, near-term business targets for 2024. As Edward Hæggström said, we are on track to meet them all. Increased number of signed projects on the non-GMP and GMP sides, improved operating free cash flow versus last year, and potentially the most important one, signing one or several license commercial supply agreements during the year. This is around Nanoform's salute, together with our partners in the Open Concept Consortium. Before we go to the product kernels, I want to briefly emphasize our key strategic points. So remember, even though we will now start to talk about product kernels, there are three parts to Nanoform's strategy. The first one is that all APIs should be. None of us should be star mapped. StarMAP is our AI engine where we can assess whether the molecule is amenable to nanoforming. It's a very cost-efficient and time-efficient way to do this. And it's also a green way because you don't have to test it in the real world. Once you have StarMAPped the molecules, you can pick the ones that are amenable to nanoforming. Here Nanoform works with partners or with customers both on novel and existing molecules. And here the idea is that, just like most of our projects where customers own the API, having problems with bioavailability or wanting to improve it, different delivery route or something, we work with them on their asset fee for service in non-GMP and GMP, and then we get the royalty for when the product is launched. However, as this is a very conservative industry and as a result of the very good results with Nanoform and the modern approach to automated systems, we have decided to produce more of these kernels, mostly in the ASD area, but also in biologics, inhaled, and long-acting forms. And here the idea is that we develop these product kernels. We early on partner with a development partner. And then we do the up to a pilot study. And then we find a commercialization partner who then takes it to the market with us in the coming years. We think this is both financially smart because the return on investment can be significant. But it's also a very important step because this is a way to prove to the industry that nanoforming is a very versatile and broad technology. So let's now go to the product kernels as a quick reminder we talk about alternatives to assess amorphous solid dispersion medicines. There are roughly 50 on the market. They sell for roughly 50 billion a year. The reason why they are amorphous is that amorphous forms have better solubility and bioavailability than crystalline forms. By using nanoforming, we could potentially achieve a substantially higher drug load. We've seen it with nanoenzalutamide, for example. Extend these four pills. We have been able to develop a 160-milligram tablet. You can reduce the pill burden. You also have the IP angle and you have the opportunity for an earlier market entry. We have STARMAPped all the APIs on the market. There are roughly fifty of them. Some 80% of them are amenable to nanoforming. We have looked at these. Here is a list of more than 30 of them. We have analyzed this from commercial, technical, and IP perspectives, and have decided that we want to have seven product kernels from this amorphous solid dispersions (ASD) group. The first two products we announced were nanoenzalutamide and nanoapalutamide. In this quarterly report, we also showcase further progress on several other product kernels. So if we look at the product kernels we have developed so far, we have already two where we have a development partner that's not only involved in solute amide together with our own concept consortium. And then we have another one where we have not yet disclosed to the development partner. Then we have four projects where we do not yet have a development partner, but where we are already having discussions. Now, for example, in Applewood tonight, we have had several discussions already and we have come quite some way already. Remember that here. The idea is that first you find a development partner and then, after conducting, for example, the pivot or the pilot study, you secure a commercialization partner. And you can see here in the green column that, around Reno. And tonight, we expect to sign with a commercialization partner this year. And then, for the rest, in the coming two years. This is an excellent way for us to showcase the technology, demonstrate its breadth and power, and also to achieve substantial and favorable returns on the investments we have made in product governance. With this, I turn it over to Christian, please. Christian, go ahead.

Unknown 1
16:42 - 16:43

Thank you.

Christian Jones
16:43 - 28:33

Albert here. Good day to all of you on the call. I'm happy to take you through the commercial highlights of the Q2 reports and move to this slide. I'd like to recap where the value proposition of our technology lies and highlight some great examples of the value we've demonstrated with our partners. Um, and we've really shown value both in vitro, in vivo, and also now through a clinical study using our technology. So first of all, in oncology we've replaced amorphous solid dispersions with nanocrystalline high drug load formulations. Perhaps that's best represented by the nanoenzalutamide case study that we've discussed. We've also been doing something very similar with nanoapalutamide. And of course, we announced this year a public relationship with Celanese. And this is around a molecule called patent applications. Um, and there are, you know, so many tablets that would be required for a patient with lung cancer. So we are looking to reduce that tablet volume and improve patient-centricity. Then we move to inhalation. In inhalation, we've been engineering nano formulations of both small and large molecules to give superior performance in the lungs with high fine particle fraction and fine particle dose. And we've been able to show performances of more than 95% versus 50% with spray drying, again representing high drug load delivery to the lungs. And you'll see a common theme in all of these points. And it's around high drug load. So in the oncology space with oral tablets, we're really focusing on increasing bioavailability while getting a very high drug load in the inhalation applications. We're talking about achieving a high drug load in the right part of the lungs, and in the biologic space, as demonstrated in partnerships with Takeda and other companies as well. This includes achieving ultra-high concentrations for subcutaneous drug delivery with acceptable viscosity for injection. Now that, you know, we've been able to demonstrate drug loads of greater than 400-500 mg per ml in some of our projects. And that's again representing a very high drug load. That's possible with nanoparticles. In the biologic space, particularly in ophthalmic applications, we've been looking at multiple projects where nanoparticles have shown improved delivery. Again, a high drug load to the eye, enabling smaller implants with no need for mesh membranes. This is something that we demonstrated with Celanese, a collaborator last year, and the ability to create ophthalmic inserts or eyedrop suspensions that can have superior delivery profiles. And then in hydrogels. A fantastic example is with PlusVitech. We were able to achieve a 200-fold improvement in drug load over the bulk drug substance. And this was only possible with our nanoforming technology. And this was five times more than the nano milling alternative. So again high drug load. And when we think about all of this, that's the common theme. But what actually backs up all of this is that we're able to do it with proprietary technology and proprietary formulations. These novel technologies, processes, and formulations can really help our partners, our innovator partners, to further protect their products, to add value to their products, to enable market opportunities, lifecycle management, and very strong launch strategies. A great example of that would be if, for example, an innovator Pharma was to actually launch their product with nanoformed oral tablets, and they were able to make a tablet that's a third of the size of anything possible with an amorphous solid dispersion. That technology and that product could be on the market, exceeding its present expiration with no generics able to copy that product. We see significant value in those types of discussions as well. So as we go to the next slide, let's just talk about some of the products that we're working on. Here is a very nice overview and updated one since the last report on our pipeline. I'd like to spend a few moments here just to discuss again where the value is and the types of projects that we're working on. The majority of our work is in the pre-clinical space and that really hasn't changed. The reason for that is because we're trying to address one of the biggest problems in the industry, as Edward mentioned at the beginning, which is that of poor bioavailability, and poor bioavailability has to be overcome before you move into first-in-man for phase one studies. Therefore, many clients come to us with projects where all other technologies have failed and they still can't get the molecule to be soluble enough. So we work on a lot of projects in that preclinical space, and that's still a core focus for Nanoform. But increasingly, as we've demonstrated value in making products more patient-centric. Once a product has been successful in phase one studies, maybe it's not optimal, but it's proven that there is efficacy and it's got good enough bioavailability. Many companies are now coming to Nanoform to say, 'Could you help us make our product more patient-centric?' Could you help us take six tablets down to a single tablet in those types of discussions? So we're seeing an increasing amount of projects now in the phase one to phase two area, where that's still an option to optimize the formulation. As we look towards the latter part of this table, we'll see the 'marketed in 505(b)(2) products.' As Albert alluded to, we started to develop these product kernels. We want to demonstrate value in that space, value that is clear. That can be clearly commercialized with our pharmaceutical partners and very often going to a major pharma company with a concept with data is a lot more credible. And so I think we're going to see a lot more traction in that space by developing these product concepts and taking them to major pharma and to other partners to see how we can commercialize them going forward. So life-cycle extension 505(b)(2)/generic opportunities here. Um, and this is where we're going to see more deals. So, you know, the earlier work in the preclinical space and moving into phase one, it's more around fee for service and trying to develop a relationship. Prove that the technology works. Once we've already established that there is value by doing these product kernels, we will be able to do deals in a much faster way with our pharma companies that we're talking to. So if we go to the next slide, I want to just talk about the highlights from this year. We've had a very positive seven to eight months. Q3 has exceeded expectations. We certainly have seen a huge momentum and drive in commercial traction. And we see that only continuing as we go through the latter part of this year. August has been a very positive month. We had the announcement with Takeda that we had initiated a collaboration on their plasma-derived therapy development. This is a continuation of the existing relationship that we have with them, and it's in the biologics space. In July, we had a new U.S. major pharma who signed a multi-API contract. Really exciting there. You know, our relationships with global top 20 pharma has now gone from ten of the top 20 to 11 of the top 20 companies that work with Nanoform in May. We were able to be present at the DF exhibition where Takeda presented on Nanoform's technology. And talked about the great data there in the high concentration biologics space for subcutaneous delivery. And since then, we've seen significant traction and interest in our technology. It's the first time that a major pharma has stood up and talked externally, and we're delighted that they were pleased to do that with us and for us. Celanese also at the same conference, without any of the masking, they were also showcasing work we'd done with them previously. And on the long-acting space at the same conference. So, we're really starting to see an increase in Nanoform's brand, its visibility, and its credibility in the industry. In April, we signed a contract with a global top five animal health company for a new multi-API contract. And we also entered into a partnership with a trading company in Japan called CBC. And that's really to expand our market access into Japan as we want to bring our technology to all corners of the earth. As we have demonstrated good traction in both Europe and the U.S., we see it as a natural progression to start to look towards Asia as well. We also mentioned the non-Performance PlusVitech partnership in April, and in February, and in January, we had fantastic announcements around Nanoapalutamide and Nanoenzalutamide preclinical promising study results and also the clinical data, the promising data around Nanoenzalutamide that was announced in January. So, a very busy 7 to 8 months, but a great start to the year. And we're very much looking forward to continuing this success as we move forward. If we look at the number of customers that have signed, we've increased that by five so far this year, but we've actually increased the number of molecules significantly more than that. So, by 13 since last year. And that's because we're starting to develop broader and deeper relationships with our major pharma partners who have deep pipelines. From an economic perspective, the markets haven't been particularly buoyant for biotech companies, but also because of the strategic intent. We want to develop deep and broader relationships with major pharma companies. This has really paid off. So, we're starting to see some of these major pharma companies giving us more than one molecule to work on at a given time. As we review the selection of partners, we have those on the right hand side that have allowed us to talk publicly about our relationship. And as you can see, we're now working, as I said before, with 11 major pharma, 35 mid-size specialty pharma, and biotech companies. We've got two co-developments. That's the Nanoenzalutamide and one that's undisclosed in our product kernels and three collaborations in the mix. If you would like to meet with us at any of our upcoming events, you can see them here. They're also on our website. Both commercial and financial events are listed here, and we very much look forward to discussing more about our technology with you. Should there be an interest? And with that, I think we close for a Q&A session.

Operator
28:37 - 29:03

If you wish to ask a question, please dial the pound key followed by the number five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial the pound key followed by the number six on your telephone keypad. The next question comes from Sammy Sakuma from Danske Bank. Please go ahead.

Unknown 2
29:07 - 29:31

Okay. Hi. I have two questions still. Firstly, on Takeda Corporation. I think you issued a release a couple of weeks ago regarding a deal you have done on biologics. Can you provide some details on what this collaboration entails and how it will proceed?

Christian Jones
29:33 - 30:08

Thanks, Sammy, for that question. I'm happy to take it. What we can disclose is what's in the press release, and it states that we have continued our relationship with Takeda, showing promising in vitro results from a proof of concept study. We are moving forward into further formulation development of a novel formulation for subsequent testing in vivo by the end of this year. That's all we can disclose, I'm afraid.

Unknown 2
30:10 - 30:26

So, is it right to assume that we are talking about preclinical activities at this point? And if those are successful, you would then start the new drug development process, beginning with phase one.

Christian Jones
30:29 - 30:43

I think you have understood what is written pretty well, but I can neither confirm nor deny that. I can only comment that what is written in the press release is what we're allowed to disclose.

Unknown 2
30:45 - 31:33

Okay. And then a slightly more detailed question. This is related to the grant you received earlier this year. I think it was about €3.7 million. I think you were planning to use the grant during this year and next, covering part of the R&D costs. I think it was reported under the other operating income line, but I am curious if it was booked in the second quarter. Any further details on when you will be recording this grant as income?

Albert Hæggström
31:34 - 32:31

Yes, hi, Sammy. Yes, we will be booking it over the coming years, under the other operating income. We book our progress as we work according to the plan. So basically, if you analyze the data from eight or ten quarters and divide the numbers, you can derive an estimate of the projected outcomes. Mostly it's work related, internal work related. Some of it can also impact, for example, if we conduct animal studies, or if we utilize outside consultants or assistance. But think of it as 8 or 10 quarters. And, we have been ramping it up now. And now the numbers are gradually increasing each quarter. But that's the best way to think about it.

Unknown 2
32:34 - 33:06

Okay. And then maybe the third question regarding the plant commercial deals, these are probably related to the nano and glutamate project. Can you provide any insight on what kind of deal structures you would like to see in place, specifically, is there a preference for upfront payments? Or would you rather pursue maximum royalties?

Albert Hæggström
33:07 - 35:07

I think that what we have said before is that there are many different kinds of deals to be made. And we do it together with our partners in the concept consortium, and we try to sort of, uh, do it the smart way. And of course, for us at this point, it might be smarter to have a broader scale. So let's not try to cover everything in the royalty line, but also secure something upfront and some of the milestones. But in the end, I think these will be deals that are quite similar to what you see in the industry. So you get something upfront, then there are milestones, and finally the part where the products are launched. And that's the way they are probably going to be. And what we have said is that we can do one or several. So think of it like what we can do for one country. We can work with one partner if, for example, they specialize in oncology or prostate cancer and are prominent in a large European market. We could also do a deal with a larger player that covers an entire area, like let's say, northern North America, Europe, or other regions. But we are now engaging and discussing term sheets with them, exploring potential deals and gauging interest. And then we'll see. As a former finance professional, I would explain it somewhat like this. When orchestrating an IPO, you engage in discussions with numerous stakeholders. But they should happen this year.

Unknown 2
35:09 - 35:12

Okay. I don't have any further questions.

Operator
35:19 - 35:24

The next question comes from Christopher Ude from SEB. Welcome everyone to Nanoform's Q2 2024 interim report presentation.

Christopher Udy
35:25 - 35:50

Christopher Udy from CBC. Thank you for taking my questions. Perhaps you could help us understand why the number of proposals issued has been increasing, but the proposal success rate has been clearly trending downward. Also, perhaps not related, but why have days of sales spiked in H1 2024? So that's my first question.

Edward Hæggström
35:53 - 35:54

Christian, would you like to take that?

Christian Jones
35:56 - 37:09

Yes, I believe you have to consider everything within a certain time period. It's easy to look at proposals issued and won on a month-by-month basis or on a quarterly basis. But what we have seen is that we've had quite a lot of discussions with biotech companies that perhaps have struggled with financing and therefore, they've been holding off on awarding a proposal, but it doesn't mean that those proposals are lost. Um, those proposals could still be active. Once they secure financing or funding, they may well be awarded. So, it could look like we haven't been as successful in winning proposals. But I think the important thing is that there are a lot of proposals out there that are active and are waiting for certain triggers. And, you know, funding is obviously an essential topic. But there are also other reasons why companies might stall or wait before taking action. And that could be due to their own strategic internal decisions.

Albert Hæggström
37:09 - 39:30

If I add something. So think about it like this. In 2020 and 2021, the biotechs were swimming in money. Everybody was in a hurry, and signings by biotechs were very fast. Then, the money became much tougher to get. On the biotech side, processes began to slow down. In many cases, they were unable to sign even if they wanted to, due to a slow funding situation. And so, funding deals. In the beginning, we had a higher proportion of biotechs compared to Big Pharma. When you look at the big pharma signings, they are much the same. The speed at the big pharma in the beginning was quite slow because this was the first deal and we had to sign. In some cases, the master service agreement requires signing up to their systems and obtaining all the necessary checklists and so forth. Once you have packaged the first API and structured everything, the subsequent processes can be faster. Generally speaking, the behavior of big pharma has not changed from the low interest rates environment of the past to today; they behave very similarly. However, their proportion of the total deals signed has increased compared to biotechs. And that means, of course, that relatively speaking, it might appear that it takes longer. But I don't think there is a significant difference when we look at the success rate. Uh, but it's too early to tell. And also remember that, uh, biologics also have an impact on it. Uh, so, uh, we don't see any clear trends in that sense; we still believe we have a high success rate. We make really good proposals. We put a lot of effort into them. Uh, we talk a lot with the clients, and, uh, we have a high hit ratio. When we look at it from the perspective of new technology in a conservative industry.

Christopher Udy
39:32 - 39:33

And the days of sales outstanding.

Albert Hæggström
39:35 - 39:57

Uh, that's, uh, uh, we haven't seen any. Over the past five years. We have had one situation where there was a minor problem with the payment. But basically, you know, uh, this is not an issue.

Christopher Udy
39:59 - 39:59

Okay?

Albert Hæggström
39:59 - 40:05

These are very much fluctuations from one month to the next; this is not an issue.

Christopher Udy
40:06 - 40:48

Right, so regarding the three multi-API deals you've concluded, and from your previous remarks, it sounded like there might be more on the table. I guess my first question would be: Are more on the table? And then perhaps you could comment on the nature of the deals. Obviously, I realize you can't be specific, but what can you say about how similar the deal structures are? Are we talking about a set number of APIs? You know, how variable is that? Are they exclusively non-GMP deals? Um, or, uh, yeah.

Edward Hæggström
40:49 - 40:50

Christian, please take over.

Christian Jones
40:51 - 42:24

Yeah. So, I would say we have everything that you just described and more besides. Um, so, a real variety of different types of discussions are ongoing. So we have some that are more proof-of-concept (POC) related, focused on individual projects, that, if successful, then progress to the next stage. We have some that are more like stage-gated contracts. So, you know, we've effectively agreed on the terms for moving forward into the next stage and onto GMP, providing we reach the successful milestones within the project. Um, then we have some that are, uh, more, uh, broader, um, in terms of strategic nature. A company might want to fast-track, for example, three or four molecules or even more at one time, in parallel with some of the big pharma companies. Based on the success of that, we will move forward with advancing some of those molecules into the next stages. We have had discussions where companies are already eager to discuss commercial terms upfront, before they have engaged in any work with us or even started a project with us. Um, and those are very interesting discussions. Um, so it really, really depends. And yes, you would be right to assume that there are more multi-API projects coming forward. Um, but we probably can't disclose more than that.

Albert Hæggström
42:25 - 43:28

And one additional thing, which is a potentially big change versus last year, is that before we never considered exclusivity on certain receptors or diseases, but now it's increasingly coming into the discussion that Nanoform might be involved. There are several companies that are now reaching out and talking about whether they can get exclusivity. This applies to both small and large molecule types, focusing on receptors or disease areas, and then, of course, such deals are not uncommon in the pharmaceutical industry; we see these kinds of partnerships on a regular basis. But of course, for us it's a positive development also because we know that our technology can offer a lot of upside and many interesting opportunities for drug developers.

Edward Hæggström
43:29 - 44:32

May I, Christopher here, also suggest that this represents an exclusivity mosaic. It's something that we spend a lot of time on with Peter and our IP lawyer, Winfred. Ultimately, there's no need to be able to play 10,000 different games. It's more important to map out the 50 or 100 games that we in practice are going to play, and this means that there is a balance between molecule, receptor, and indication. And we are starting to learn this. And of course, the clients have their viewpoint. We have our viewpoint. But I have seen that these discussions are clearly much more mature than the similar kind of discussions that we had with more technical people earlier on. So this is an interesting thing, the exclusivity mosaic and how that is developing.

Christopher Udy
44:36 - 44:37

Thanks.

Unknown 2
44:38 - 44:39

In terms.

Christopher Udy
44:39 - 44:49

Regarding the GMP project signing that you reported. Uh, is this a customer project or an own project, Colonel?

Edward Hæggström
44:50 - 44:52

This is a customer project.

Christopher Udy
44:54 - 45:28

Uh, and the. So. All right, uh, obviously you have this deal with Takeda. The intent is to go all the way. It, uh, how I interpret the press release. Um, if everything works out, uh, what are your plans for a bio GMP line? Um, because obviously you have three that are built right? And finished now, uh, on the west side, should we assume that you're going to likely be doing some CapEx for the bio side?

Edward Hæggström
45:30 - 46:23

So maybe, if I start, and then Albert can add on. Our strategy for the, uh, access side was: build it and they will come on the GMP side for the biologics. We have stated that our strategy is that we will, together with a partner, invest in the GMP for the biologics. On the biologics side, what we have already done is to do extensive planning work. Uh, for what the bio GMP facility could look like here using our tech platform. And uh, I think we are moving in the right direction. What we also do, which is relevant to that, is we do active industrialization on the biologics side, which means that we will have a very good understanding of what scaling up means and what the GMP aspects will entail. Elmer, do you want to add something?

Albert Hæggström
46:24 - 48:03

Yeah. I mean for us, we have built the clean rooms and everything on the small molecule side, we have SAP installed, we have the staff. We also have the QMS systems and the likes. So for us, it's more a continuation of what we've already started. Remember also that on the biologic side it's a little bit more customized depending on what kind of products you are making. This is in contrast to the small molecule side. But for us it's very clear that we have already accomplished this on the small molecule side. And then, when the customers specify exactly what they want on the biologic side - whether it's subcutaneous, inhaled, or potentially even oral, or if it's a sterile product or IV - it will be somewhat different. So, we will undertake it with a partner. And we feel that this step is much smaller compared to what we have already done because we've taken the first step on the small molecule side. So we also anticipate that the CapEx will not be that significant. And Chris, you have seen the lines. So you know that the biologics lines are not that extensive. Therefore, we are not talking about a really large footprint here. We are discussing very clever technology that fits into a room. So that also helps when it comes to GMP scale-up and these are clever technologies with a small footprint and low CapEx.

Christopher Udy
48:06 - 48:15

Thanks. And then, um, can you remind us, uh, have you fully finalized the formulation work for nano enzalutamide?

Edward Hæggström
48:18 - 48:51

Um, so I need to answer a little carefully. Now, um, we have done formulation work on nanoenzalutamide, and that takes us into the response domain where we need to be. We have not finalized the nanoformulation work on nanoenzalutamide in the way that it is the one that's going to go into a marketed nanoenzalutamide product.

Christopher Udy
48:52 - 49:07

Got it. Okay. That's what I thought. And how much time will that likely take? Are you waiting until you sign to do that? Yeah.

Edward Hæggström
49:08 - 50:20

I think that's a very, very good question. And I would like to answer it in the following way. We have already now sufficient formulation results that we can continue to do the two tracks. One is the originator track and the other is the non-originator track. I also think it is smart to continue to improve the formulation for two reasons. One, I believe that the formulation will give strategic options, both for the originators and for the others. So the better you make it, the more valuable it is. I also believe that all the work we do on Insulatard will partly be relevant to the nanoapalutamide work. And I also think that in the ASD class there will be other classmates, if you like, that will benefit from what we do on this sort of first in this nanocrystalline modified class. So a long answer, but your question is good and it's an important one.

Albert Hæggström
50:20 - 50:50

And remember, in nanoenzalutamide and nanoapalutamide all stem from the same original molecule in a sense. You get learnings and, but related to the timelines. What we have said is that we expect to get the readouts from the studies early next year.

Unknown 1
50:51 - 50:52

Right.

Christopher Udy
50:52 - 50:58

And then?

Albert Hæggström
50:58 - 51:18

Sorry to interrupt, but also the deals can be done before you have the results. So the deals are done already earlier. This is again, some clients want to do them really early on. Some clients do want to wait more, but the deals should be done this year.

Christopher Udy
51:19 - 51:30

Then the 31 out of 39 sites that you've predicted would be unaffordable. What's the problem with the other eight?

Edward Hæggström
51:32 - 51:54

I think it's a matter of bandwidth. So I always think of this list: rank, prioritize, focus, and park. In order to maximize the probability of driving performance, the company forward, I think it's smart to do what I just said. So that's the reason.

Albert Hæggström
51:54 - 52:10

And remember also that some of them, if they are really poorly soluble in supercritical CO2, are not good candidates. Uh, so that's one reason.

Christian Jones
52:11 - 52:20

Absolutely. Do you remember that slide, Chris? Did you mean to say that 80% of APIs were amenable to nanoforming? Um, that's why, you know, 30 or 31 out of 39.

Unknown 1
52:21 - 52:21

Yeah.

Christopher Udy
52:22 - 52:31

And then lastly, is there any indication that you can give of the R&D cost per project kernel?

Edward Hæggström
52:32 - 52:56

Uh, it's low, and Albert will give it a bit more financial flair. But the way we have structured it is very interesting, where we can create a lot of value at a very low cost position because of what we have in-house and because of how we structure the deals. However, Albert may offer a financial perspective.

Albert Hæggström
52:56 - 54:50

Yeah, I mean, if you look at it from a cost point of view, you see that when we do the work, we get 75% of it funded by the partners when they do the work. We cover a quarter of it, and you can see that the external R&D expenses line has not moved very much, even though we have developed these product kernels. So they have been, you know, changing between 200,000 and 500,000 per quarter. And, the idea here is, of course, that when we conduct the clinical trials, they are a little more expensive because they are done externally, but otherwise, a lot of the work can be conducted within Nanoform and with our partners. For example, Blue Pharma is formulating the final drug product into tablet form. And that's also a very cost-efficient way of doing it. So when Nanoform is developing these drug kernels, it's very different compared. If you are a biotech with no internal resources and need to outsource everything. And, of course, we can also proceed when we have. So if we have, you know, 20 plus projects running in parallel in a year and, at the same time, we are doing these. Some of the projects we are working on are internal, while most of them are customer projects. So it's also about timing the work so that if you have a slower month, then you can do more work on the internal projects. Customer projects always come with a high priority, of course.

Christopher Udy
54:52 - 54:54

Okay, great.

Edward Hæggström
54:56 - 54:56

Thank you.

Operator
55:03 - 55:09

The next question comes from James Osborne from Stifel. Thank you for joining us today as we discuss Nanoform's performance and strategic directions in the second quarter of 2024.

James Osborne
55:10 - 55:41

Hi, Edward. Appreciate you taking my questions. And just on the tequila collaboration, if I may, I think Christian, you mentioned it's had a pretty immediate impact in terms of the incoming on potential projects. I wondered if you would be able to quantify or provide more detail about the impact that this kind of presentation and collaboration has had thus far. I appreciate it early, but also, I guess, how it's going to gain exposure to the Japanese market and how you see that working in the mid to long term.

Edward Hæggström
55:41 - 55:44

Particular question.

Christian Jones
55:46 - 57:56

Sure. I think this space is a very interesting one. In terms of high concentration, per unit volume, drug load delivery for subcutaneous administration in biologics. There are other players in the market that aim to enhance the delivery of monoclonal antibodies and other proteins to patients by partnering with companies like Celanese. We're starting to engage with pharma companies now, discussing what the commercial terms could look like for using our technology, and we are beginning to enter some really interesting discussions. And I think, um, you know, when we consider looking back at the technology and where we might have been a few years ago on a parallel track, we certainly didn't have the level of commercial interaction that we are seeing with biologics now. Back then, although we were having some very exciting commercial conversations around the small molecule platform. It has taken a lot longer to reach that position with the biologics platform than originally anticipated. I think the data is really exciting. There is a clear need for these types of product innovations. Um, and I think that's what's driving that level of traction. We're seeing a lot of interest from major pharmaceutical companies through to smaller clients around higher concentration drug delivery for subcutaneous administration for biologics. Equally, I think that has also made those companies in that space, who have products but may be looking for different routes of administration. Um, they're also coming to us to say, 'Well, okay, this sounds great.' Looks like you can make stable dry powder biologic nanoparticles. Maybe we could use them for different routes of administration. This provides a novelty and value addition that isn't possible with other technology. So, um, that's perhaps what I can say.

Unknown 2
57:56 - 57:58

James James.

Edward Hæggström
57:58 - 59:18

Can I answer a bit tangentially to that question? I think one thing that has been clear is that the results we have obtained now have allowed us to communicate on a higher level, both with potential partner companies and our client companies. These discussions can essentially be summarized in a single sentence. What kind of new strategies and strategic tweaks can we enable for them that they did not have in their strategic palette before? And this is something which we have never been able to do in previous years. The timeline for when this will matter under Roy is hard to estimate, but from my perspective, it's absolutely clear that this is a significant step. I just heard a rumor that one of our clients had questions in their calls about what Nanoform is doing and what they are doing with Nanoform.

James Osborne
59:21 - 59:53

That's great. Following on from that, I was looking at the cadence of signing new agreements. It seems like you've got eight signed already in Q3 with a bit of time to go, which I think is close to a new record for you guys. Are you suggesting a shift in terms of your company profile? Is that indicative of you being more recognized by potential clients or perhaps adjusting due to the funding environment? You are rising with the release of funding, achieving better rates, and moving in the right direction.

Christian Jones
59:54 - 60:28

I'm sorry, I think funding is clearly one factor that's supporting and driving the commercial discussions we're having. But the other factor is that we are maturing as an organization and starting to make a significant impact, We approach our partnerships with more assurance. They should really commit to partnerships with us.

James Osborne
60:32 - 60:49

Okay. Great. Thank you, thank you. And one question for Albert. In terms of timing and related matters. Like that. Okay.

Albert Hæggström
60:55 - 61:20

It was a bit difficult to hear you, but if you asked about the gross margin, then I would say that we have already started planning the insourcing of GMP QC work, which should begin to impact Q4. And as you know, our target is to improve the gross margin.

Unknown 1
61:35 - 61:36

Was that clear?

Operator
61:36 - 61:43

There are no more questions at this time. So, I hand the conference back to the speakers for any closing comments.

Henry von Hartmann
61:45 - 62:05

James, we had a fairly poor connection at the end, but thank you for the questions. So, thank you, operator. On behalf of Nanoform, I would like to thank all participants for today. If you have more questions, please do reach out to us, and we wish everyone a great Thursday afternoon and evening. Thank you and goodbye.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…